Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NICE IP: Nivolumab vs S-1 as Second-line Therapy for NSCLC with Interstitial Pneumonitis
jRCTs031240432Phase 3Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in non-small cell lung cancer (NSCLC) and interstitial lung disease (ILD) comparing Group A: S-1 with Group B: Nivolumab (2 arms). Primary endpoint: Overall Survival. Started Nov 2024; status: recruiting.
02
Drugs
nivolumabtegafur
03
Conditions
non-small cell lung cancer (NSCLC)interstitial lung disease (ILD)
Beyond the preview
Go deeper on jRCTs031240432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240432.